Back

Post-PCI anticoagulation with unfractionated heparin in acute coronary syndrome: insight from the STOPDAPT-3 trial

2 September 2024 (10:06 - 10:18)
Organised by: Logo
Congress Presentation Part of: Tailored approaches to cardiovascular therapy in acute coronary syndromes Pharmacotherapy ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Hirotoshi Watanabe

Hirakata Kohsai Hospital, Hirakata (Japan)

4 More presentations in this session

Presentation thumbnail
Effect of alirocumab on coronary plaque stratified by atherothrombotic risks
Doctor Y. Ueki (Matsumoto, JP)
Abstract Slides Video
Presentation thumbnail
Lesion-level changes induced by low-density lipoprotein cholesterol lowering therapy in patients with acute myocardial infarction: the pre-specified PACMAN-AMI lesion-level analysis.
Doctor F. Biccire (Bern, CH)
Abstract Slides Video
Presentation thumbnail
Real-world evidence supports superior efficacy of prasugrel over ticagrelor in individuals with acute coronary syndrome
Doctor N. Kruger (Boston, US)
Abstract Slides Video
Presentation thumbnail
A liberal blood transfusion strategy is safe in patients with myocardial infarction, anemia, and heart failure: lessons from MINT
Doctor A. Goldsweig (Springfield, US)
Abstract Slides Video

Access the full session

Session thumbnail
Tailored approaches to cardiovascular therapy in acute coronary syndromes
Video

The Event

Event poster

ESC Congress 2024

2 September 2024 10:06 CET
You may be interested in
thumbnail
Congress Presentation
A comparison of prolonged anticoagulation versus no anticoagulation after primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction
thumbnail
Congress Session
HOT LINE 6
thumbnail
Congress Presentation
Clopidogrel following 1-month aspirin-free low-dose prasugrel monotherapy versus aspirin following 1-month DAPT after PCI for patients with ACS or HBR: Final 1-year results from the STOPDAPT-3

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources